Enanta Pharmaceuticals, Inc. (ENTA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
4 Kingsbury Avenue
Watertown, MA 02472
United States of America (the)
Phone
617 607 0800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
120
First IPO Date
March 21, 2013
| Name | Title | Pay | Year Born |
| Jay R. Luly | President, Chief Executive Officer & Director | 742,273 | 1956 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 496,852 | 1978 |
| Matthew Kowalsky | Chief Legal Officer & Corporate Secretary | 575,652 | 1973 |
| Brendan Luu | Chief Business Officer | 622,856 | 1975 |
| Nathaniel S. Gardiner | Consultant | 672,675 | 1954 |
| Yat Sun Or | Chief Scientific Officer | 814,285 | 1952 |
| Scott T. Rottinghaus | Chief Medical Officer | 863,706 | 1974 |
| Harry R. Trout | VP of Finance & Interim Principal Financial Officer | 0 | 1969 |
| Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | 0 | N/A |
| Kathleen S. Capps | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | 0 | 1985 |
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.